Trial Profile

A Phase I Clinical Study on the Safety, Pharmacokinetics and Pharmacodynamics of Oral APG-115 Capsules in Patients with Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alrizomadlin (Primary)
Indications Adenoid cystic carcinoma; Liposarcoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions
Sponsors Ascentage Pharma

Most Recent Events

31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Results published in the Ascentage Pharma Media Release.
31 May 2020 According to an Ascentage Pharma media release, latest clinical data from this study were presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO20).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com